CK Clinical are proud to announce the new member of our Drug Safety and Medical Information Recruitment team, Krishna Pankhania.
Speaking of Krishna’s arrival, Hendre Moolman, Senior Consultant at CK Clinical team, stated,
“We are delighted to welcome Krishna Pankhania to the Drug Safety and Medical Information team. She comes from a Biochemistry Research background and will be assisting the team in recruiting for permanent and contract vacancies in the UK.”
Krishna, a Biochemistry graduate from the University of Nottingham, is extremely excited about her new position here at CK and stated, “When I left University I knew I wanted to work in recruitment because I like interacting with people and wanted a job that was diverse and rewarding. In my search for the perfect start to my career I found CK Clinical, I am now happily working with the CK Clinical team and very quickly learning the in’s and out’s of the Pharmaceutical Industry. I am thoroughly enjoying my time here. The team are friendly, welcoming and always at hand to help.
CK Clinical is outstanding because it’s a company that is successful in building professional relationships with some of the top clients in industry as well as adopting the most honest and sincere work ethics. They also take great care in helping candidates and always have their best interests at heart. I can easily say I am proud to become part of the team!”
As reported by Fierce Pharma, the global pharmaceutical companyEli Lillyis planning to close its Singapore based Centre for Drug Discovery which could lead to 130 pharmaceutical jobs to be axed.
The move comes as the pharma company attempt to make worldwide cost savings. The plan is to select the best research programmes and shift them to their headquarters in Indianapolis.
Lilly will continue to operate a Phase I clinical which is known as the Lilly NUS (National University of Singapore). In addition, it’s marketing and sales affiliate will stay put, as well as various scientific collaborations with universities and research institutions.
We are proud to reveal that CK Clinical has been announced as a finalist in the NORA’s 2010 (National Online Recruitment Awards).
CK Clinical is pleased to have been shortlisted for the Best Newcomer in Online Recruitment Award. It really is a great recognition of all hard work and passion that has been invested into ensuring the CK Clinical website is the best that it can be.
This year, a massive 28,000 nominations were made for 592 separate recruitment websites. We would therefore like to take this opportunity to say a huge thank you to all those who took the time to nominate the CK Clinical website, it is greatly appreciated
Speaking of the Finalists, Founder of the NORAs, Stephen O’Donnell said, “We are proud to announce the most diverse shortlist of Finalists in the history of the NORAs. The standard this year, particular amongst UK employers, has greatly impressed, and shows a marked advancement in progressive and sophisticated recruitment methods via the Internet.”
We are very much looking forward to the awards event on Thursday 4th November – fingers crossed!
To find out more about the NORA’s, please click here.
Be the first to know of pharmaceutical jobs you may be interested in by signing up to CK Clinical’s new pharmaceutical job alerts now.
Staying ahead of the game is often key to successful job hunting in the pharmaceutical industry. By signing up to our alerts you can be sure that you won’t miss out on your next great opportunity within the pharma industry.
Simply click on the link below, fill in your details along with some keywords relevant to the type of job you’re looking for and you will be automatically alerted via email as soon as any relevant pharma jobs are published to our website.
As reported by the Financial Times, the Basel-based pharmaceutical company Roche announced significant job losses, most notably in research and development.
The job cuts have arisen in response due to recent setbacks on key drugs and rising pressures on prices resulting from healthcare reforms.
Roche is the world’s largest maker of cancer drugs and has had recently had blows to their development programme and invectors are now waiting to see if the FDA will revoke approval for their blockbuster cancer drug Avastin.
In a statement, Roche stated, “In view of mounting pressures to curb healthcare costs — especially in the United States and Europe — together with recent developments in late-stage projects in the Roche pipeline, this initiative aims to adapt cost structures and accelerate productivity improvements group-wide.”
As of yet there are no definite details regarding the size of the cost reductions and number of staff. Further information will be released later this year and the cuts are scheduled for 2011/2012.
As reported by the Wall Street Journal, Eisai, the Tokyo-based pharmaceutical company, has been given another weapon by the FDA against competition from generics companies for its Alzheimer’s drug Aricept – a higher dosage form of the drug has now been approved by the agency.
According to recent studies, patients using this higher dosage (23-mg) drug got better results than those using the lower dose. So, even though the 10-mg version is due to be released in November, Eisai is hopeful that the approval of the higher dosage drug will keep the generic lower dosage version from slashing sales.
Meanwhile, Eisai is reportedly planning to move their manufacturing to India with the main aim of lowering overall production costs of Aricept. This will enable the company to compete with the generics makers.
As we hope you are aware, over the last 9 months the CK Clinical website has had a face-lift. With a new fresh design, and frequently updated content, we really hope that you have found the site to be a useful aid in your job search.
Here at CK Clinical, we are extremely proud of our online presence. So much so that we would really appreciate it if you could spare a minute of our time to nominate our website in the National Online Recruitment Awards.
To nominate CK Clinical’s website in the National Online Recruitment Awards, please complete the registration form.
Congratulations to our two Recruitment Consultants, Meera Pattni and Andrew Bolton for passing their REC in Diploma in Recruitment Practice with flying colours!
Meera and Andrew covered four modules as part of the diploma programme including:
The Recruitment Process
Recruitment Law & Ethics
The Recruitment Project
Practical Interviewing Skills
The Diploma in Recruitment Practice is one of the recruitment industry’s leading qualifications and aims to give recruiters detailed knowledge and confidence to provide clients and candidates with a high quality consultancy service.
Meera Pattni, a Recruitment Consultant at CK Regulatory, specialises in Regulatory Affairs Recruitment. You can contact Meera at email@example.com.
Andrew Bolton, a Recruitment Consultant at CK Science, specialises in recruitment for the chemical and food industries. You can contact Andrew at firstname.lastname@example.org.
CK Clinical is currently working with a Senior Clinical Research Associate looking for work in the South West of England to help him find a suitable role. He is looking for either contract or permanent work.
He has over 5 years experience as a CRA as well as nursing experience. Having worked in a pharmaceutical and CRO environment in phases I – IV he has strong therapeutic knowledge of Oncology and Diabetes.
For more information about this gentleman or to arrange an opportunity to meet with him, please contact me at email@example.com or call on 01438 743047 quoting Ref: 0098982.